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For patients presenting with an acute ST-segment elevation myocardial infarction (STEMI), the most effective therapy for reducing myocardial infarct (MI) size, preserving left ventricular (LV) systolic function, and improving clinical outcomes is timely myocardial reperfusion by primary percutaneous coronary intervention (PPCI). Although the process of myocardial reperfusion is critical for myocardial salvage, paradoxically it can also induce cardiomyocyte death, thereby mitigating the full beneficial effects of myocardial reperfusion in terms of MI size reduction and myocardial salvage-a phenomenon which has been termed 'lethal myocardial reperfusion injury'. 1 The fact that a therapeutic intervention administered solely at the time of myocardial reperfusion can reduce MI size by up to half suggests that lethal myocardial reperfusion injury may actually contribute up to 50% of the final MI size. 1 Although the process of myocardial reperfusion has been further optimized by recent advances in antiplatelet (e.g. prasugrel and ticagrelor) and antithrombotic (e.g. bivalirudin) therapy, there is still no effective treatment for reducing lethal myocardial reperfusion injury in PPCI patients. Over the years a number of therapeutic strategies with proven efficacy for reducing lethal myocardial reperfusion injury in experimental studies [e.g. antioxidants, calcium channel blockers, antiinflammatory agents, hypothermia, erythropoietin, protein kinase C (PKC)-d inhibition] have produced disappointing results when investigated in the clinical arena as adjunctive therapy to PPCI. The reasons for this failure to translate cardioprotection into the clinical setting can be attributed to a number of factors including inappropriate animal MI models and poorly designed clinical studies. 2 However, more recently, a number of novel therapeutic strategies (such as ischaemic postconditioning, 3 -5 atrial natriuretic peptide, 6 cyclosporin-A, 7 and remote ischaemic preconditioning 8 ) have been reported in proof-of-concept clinical studies to reduce MI size when administered at the time of PPCI (see Table 1 ). To this expanding list of promising cardioprotective interventions, we can now add exenatide (Byetta), 9 an agent which has been recently introduced as adjunctive therapy for improving glycaemic control in patients with type 2 diabetes. Exenatide, which is a synthetic version of exendin-4, a peptide which was originally isolated from the saliva of the Gila monster (a venomous lizard), is a long-acting analogue of glucagon-like peptide-1 (GLP-1), a hormone released into the gastrointestinal tract which stimulates insulin secretion resulting in lower blood glucose levels. Because GLP-1 is rapidly broken down in the body by the enzyme dipeptidyl peptidase-IV (DPP-IV), its therapeutic application as a treatment for diabetes has been made possible using DPP-IV-resistant GLP-1 analogues (e.g. exenatide or liraglutide) and DPP-IV inhibitors (e.g. sitagliptin, vildagliptin, and saxagliptin). Interestingly, in addition to its metabolic effects, GLP-1 has also been reported in experimental studies to have receptor-mediated beneficial effects on the heart which include increasing myocardial glucose uptake, an inotropic effect, and protecting the myocardium against acute ischaemia-reperfusion injury (IRI), through the activation of known prosurvival signalling pathways such as phosphatidylinositol 3-kinase (PI3K) -Akt and protein kinase A (PKA). 10 ( Figure 1) . A prolonged intravenous infusion of GLP-1 has been reported in a small proof-of-concept clinical study to have a modest inotropic effect in PPCI patients with poor LV systolic function.
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Interestingly, experimental studies have also reported cardioprotective effects with the GLP-1 analogues (exenatide 12, 13 and liraglutide 14 ) and DPP-IV inhibitors (sitagliptin 15 ) . Exenatide administered at the onset of myocardial reperfusion reduced MI size in the ex vivo rat heart 12 and in the more clinically relevant closed-chest porcine heart, 13 thereby providing the evidence required for investigating exenatide in the clinical setting. Lonborg et al. 9 have investigated the effects of exenatide administered as an adjunct to myocardial reperfusion in PPCI patients. The authors found that the administration of an intravenous 6 h infusion of exenatide initiated 15 min prior to PPCI increased the myocardial salvage index at 3 months from 0.62 to 0.71 and reduced the MI size/AAR (area at risk) ratio from 0.39 to 0.30. Interestingly, .90% of patients were not diabetic, illustrating that the beneficial effect of exenatide on myocardial salvage was observed in non-diabetic patients, broadening its potential clinical application to all patients. There were no Evidence for the existence of lethal myocardial reperfusion injury in each case is illustrated by the fact that the intervention applied at the time of myocardial reperfusion was able to reduce MI size. Large multicentre clinical trials are now needed to confirm these findings and determine if there is any benefit on major clinical outcomes. AAR, area at risk; ANP, atrial natriuretic peptide; AUC, area under the curve; CK, creatine kinase; CMR, cardiac magnetic resonance; LV, left ventricular; MI, myocardial infarct; SPECT, single photon emission computed tomography.
reported cases of hypoglycaemia in patients treated with exenatide in this study, although hypoglycaemia is a potential risk in diabetic patients chronically treated with exenatide, particularly when used as an adjunct to other diabetes medications. The authors are to be congratulated on the careful design and execution of this proof-of-concept clinical study which is one of the first to use cardiac magnetic resonance imaging (CMR) to assess myocardial salvage in PPCI patients. Experience obtained from previous clinical studies has highlighted several key considerations in the design of clinical studies for investigating therapeutic strategies aimed at reducing lethal myocardial reperfusion injury in PPCI patients. Lonborg et al. 9 initiated the 6 h intravenous infusion of exenatide (25 mg in 250 mL of normal saline) 15 min prior to myocardial reperfusion and showed that blood plasma levels of exendin-4 (the active component of exenatide) were 0.177 nmol/L at the end of the PPCI procedure, which was found to be comparable with those used in their previous ex vivo small animal study. 12 Interestingly, diabetic patients on chronic exenatide therapy receive a regular dose of 5 or 10 mg twice daily by subcutaneous injection, which gives a peak 2.1 h plasma concentration following a 10 mg dose of 211 pg/mL or 0.05 nmol/L. Therefore, whether a diabetic patient on regular exenatide treatment who presents with a Figure 1 A scheme illustrating the potential cardioprotective signalling pathways through which exenatide may reduce myocardial infarct size and protect the heart against lethal myocardial reperfusion injury. The actual mechanism underlying the cardioprotective effects elicited by exenatide remains to be elucidated, although it is assumed that many of the beneficial effects are mediated through the activation of the glucagon-like peptide-1 (GLP-1) receptor on the cardiomyocytes. The activation of this receptor then recruits pro-survival signalling cascades such as the phosphatidylinositol 3-kinase (PI3K)-Akt and adenylate cyclase (AC) -cAMP -protein kinase A (PKA) pathways which protect the heart against acute ischaemia -reperfusion injury through a number of potential mechanisms including: the inhibition of the mitochondrial permeability transition pore (mPTP), the activation of AKAPs (protein kinase A-anchoring proteins), increased myocardial glucose uptake (possibly via p38 mitogen-activated protein kinase and iNOS), reduced apoptotic cell death, and the transcription of cardioprotective factors (such as PPAR-b/d, Nrf-2, and HO-1). eNOS, endothelial nitric oxide synthase; GSK, glycogen synthase kinase; HO-1, haem oxygenase 1; iNOS, inducible nitric oxide synthase; NO, nitric oxide; Nrf-2, nuclear respiratory factor 2; PKC, protein kinase; PKG, protein kinase G; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species.
Editorial STEMI also accrues similar beneficial effects on myocardial salvage is unknown; (iii) Selection of relevant endpoints. An intervention which is administered at the time of PPCI to reduce lethal myocardial reperfusion injury (as evidenced by a smaller MI size) will only impact on related endpoints such as LV systolic function, the incidence of heart failure, and cardiovascular death, and is unlikely to impact on unrelated endpoints such as rates of coronary revascularization or non-fatal MI. Lonborg et al.
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found that exenatide did not influence peak plasma troponin-T in the immediate 18 h time-frame, or MI size and LV ejection fraction 3 months post-PPCI. Whether a difference would have been seen if the area under curve (AUC) plasma troponin-T had been measured is unknown. The study also reported no difference in clinical outcomes at 30 days, although it was not powered to assess this endpoint.
CMR has emerged as a novel technique for measuring myocardial salvage (AAR minus the MI size) in PPCI patients, thereby enabling the assessment of the efficacy of a therapeutic intervention for reducing lethal myocardial reperfusion injury in the STEMI patient. The AAR can be retrospectively measured in STEMI patients within 1 week of PPCI using T2-weighted CMR to detect the extent of myocardial oedema (which has been shown to correspond to the AAR). 16, 17 The MI size can then be measured by late gadolinium enhancement CMR, and myocardial salvage calculated. Importantly, the extent of myocardial salvage assessed by CMR has been reported to predict clinical outcomes in PPCI patients, thereby confirming its importance as a surrogate clinical endpoint. 18 Lonborg et al.
measured the AAR with a CMR scan performed 2 days post-PPCI, whereas the MI size was assessed on the CMR scan performed at 3 months. Over the course of 3 months it is well known that the extent of an MI reduces in size due to infarct remodelling and shrinkage, and their calculation of myocardial salvage may not be accurate. There has also been some concern that therapeutic interventions capable of reducing lethal myocardial reperfusion injury in PPCI patients may actually decrease the extent of myocardial oedema, thereby reducing the size of the AAR, resulting in an inaccurately calculated myocardial salvage index. However, we can be reassured that for exenatide at least there was no change in the size of the AAR. 9 In summary, using CMR to assess myocardial salvage, Lonborg et al. 9 have demonstrated that a single infusion of the GLP-1 analogue, exenatide, administered at the time of PPCI improved myocardial salvage and reduced MI size/AAR in both diabetic and non-diabetic STEMI patients, thereby confirming the existence of lethal myocardial reperfusion injury in man and demonstrating it to be a viable target for cardioprotection. In addition, the findings from this study illustrate the potential dual actions of certain antidiabetic drugs (such as the GLP-1 analogues and the DPP-IV inhibitors) to lower blood glucose levels on the one hand while also conferring cardioprotection on the other. Whether exenatide can improve clinical outcomes in this patient group remains to be determined in a large multicentre randomized clinical trial. Furthermore, whether it is cardioprotective in other clinical settings of acute IRI such as in thrombolysed STEMI patients or in patients undergoing coronary artery bypass graft surgery needs to be explored.
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